SCHEMBL3255208

SCHEMBL3255208

COC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC4CCNCC4)cc3c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 2/20 0.48
TDP1 Q9NUW8 4/20 0.44
BRAF P15056 1/20 0.42
HTR4 Q13639 1/20 0.40
KDR P35968 1/20 0.40
HSD17B10 Q99714 1/20 0.38
MAPT P10636 8/20 0.37
POLB P06746 5/20 0.37
TP53 P04637 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
THRB P10828 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PIK3CG P48736 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251014 0.93 TDP1 (0.53) PARGTDP1BRAFMAPTPOLB
SCHEMBL3252622 0.92 TDP1 (0.54) PARGTDP1BRAFMAPTPOLB
SCHEMBL3254905 0.91 PARG (0.45) PARGTDP1BRAFKDRHSD17B10
SCHEMBL13928154 0.90 PARG (0.46) PARGTDP1BRAFKDRHSD17B10
SCHEMBL3250747 0.90 PARG (0.43) PARGTDP1BRAFHTR4KDR
SCHEMBL3245470 0.90 PARG (0.50) PARGTDP1BRAFHTR4KDR
SCHEMBL3254149 0.90 TDP1 (0.43) PARGTDP1BRAFKDRHSD17B10
SCHEMBL3253347 0.88 PARG (0.42) PARGTDP1BRAFHTR4KDR
SCHEMBL3245466 0.88 PARG (0.42) PARGTDP1BRAFHTR4KDR
SCHEMBL3255497 0.88 TDP1 (0.42) PARGTDP1BRAFHTR4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PARG 3507/4885TDP1 1098/4885BRAF 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.